Risk factors for death from COVID-19 identified in Wuhan patients
The odds of dying in the hospital increased with age, higher SOFA score, and D-dimer level exceeding 1 mcg/L.
MACE benefits with dapagliflozin improve with disease duration
Findings suggest treatment with the SGLT-2 inhibitor should be initiated early in some high-risk patients.
Tools for preventing heart failure
SNOWMASS, COLO. – “There will be more than 1 million new cases of heart failure this year, and the vast majority of them could have been prevented...
Noninjectable modes of insulin delivery coming of age
Treatment of heart failure with preserved ejection fraction is a work in progress
Although the disorder has a lower mortality than heart failure with reduced ejection fraction, it places a significant burden on health care...
Farxiga granted Priority Review for treatment of adults with HFrEF
The Food and Drug Administration is reviewing dapagliflozin for reducing the risk of cardiovascular death or worsening of heart failure in adults...
ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
LOS ANGELES – Use of novel oral anticoagulants may be preferred over vitamin K antagonists in patients with diabetes and AFib.
New heart failure trial data presage guideline revisions
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics